Article

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer

2022-03-17

Abstract excerpt

Oncogenic mutations within the epidermal growth factor receptor (EGFR) are found in 15-30% of all non-small cell lung carcinomas. The term exon 19 deletion (ex19del) is collectively used to refer to more than 20 distinct genomic alterations within exon 19 that comprise the most common EGFR mutation subtype in lung cancer. Despite this heterogeneity, clinical treatment decisions are made irrespective of which EGFR...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 73f66846-07d6-5715-8799-fca848374212
DOI: 10.1101/2022.03.16.484661

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancerDOI 10.1101/2022.03.16.484661Read

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer.Semantic proximity Read

The EGFR Exon 19 Mutant L747-A750&gt;P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung AdenocarcinomaSemantic proximity Read

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors: A single-center ambispective cohort study.Semantic proximity Read

EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.Semantic proximity Read

Coupled Solvent and Protein Dynamics Confer Differences in Exon-19 Deletion Mutants of the Epidermal Growth Factor Receptor KinaseSemantic proximity Read

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations.Semantic proximity Read

Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry).Semantic proximity Read

Structure-based classification for differential tyrosine kinase inhibitors efficacy of EGFR exon 19 deletions in non-small cell lung cancer.Semantic proximity Read

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancerSemantic proximity Read

Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.Semantic proximity Read

Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangementsSemantic proximity Read

A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinomaSemantic proximity Read